Sinonasal mucosal melanoma treatment response assessment to immune checkpoint inhibitors using hybrid positron emission tomography imaging

Sci Rep. 2023 Nov 1;13(1):18847. doi: 10.1038/s41598-023-45705-z.


The purpose of this retrospective study was to investigate response of sinonasal mucosal melanoma (SMM) patients to treatment with immune checkpoint inhibitors (ICI), using hybrid PET imaging. Fifteen SMM patients underwent hybrid PET imaging before and three months after initiation of ICI. The disease-specific survival (DSS) was calculated. Quantitative PET parameters of the primary tumor and their association with DSS and therapy response were investigated. Nine of the fifteen (60%) patients responded to ICI therapy. Patients with therapy response depicted on hybrid PET imaging had better DSS than those without (p = 0.0058). Quantitative PET parameters of the initial PET harbored no association with DSS or therapy response. However, these findings lack of sufficient statistical power and must be interpreted with caution. The first restaging PET-imaging after ICI initiation can help stratify patients with regard to DSS.

MeSH terms

  • Fluorodeoxyglucose F18
  • Humans
  • Immune Checkpoint Inhibitors / pharmacology
  • Immune Checkpoint Inhibitors / therapeutic use
  • Melanoma* / diagnostic imaging
  • Melanoma* / drug therapy
  • Melanoma* / pathology
  • Paranasal Sinus Neoplasms* / pathology
  • Positron Emission Tomography Computed Tomography / methods
  • Positron-Emission Tomography
  • Retrospective Studies


  • Immune Checkpoint Inhibitors
  • Fluorodeoxyglucose F18